Shares of ArQule, Inc. (NASDAQ:ARQL) have been given an average rating of “Buy” by the seven analysts that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $4.33.
ARQL has been the subject of several recent research reports. BidaskClub raised ArQule from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 24th. Leerink Swann raised ArQule from a “market perform” rating to an “outperform” rating in a research report on Thursday, April 5th. Zacks Investment Research cut ArQule from a “buy” rating to a “hold” rating in a research report on Wednesday, March 21st. B. Riley set a $4.00 price objective on ArQule and gave the stock a “buy” rating in a research report on Monday, March 26th. Finally, ValuEngine raised ArQule from a “sell” rating to a “hold” rating in a research report on Thursday, March 15th.
In related news, insider Value Fund L. P. Biotechnology sold 2,230,373 shares of the stock in a transaction that occurred on Wednesday, April 18th. The stock was sold at an average price of $3.10, for a total transaction of $6,914,156.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Value Fund L. P. Biotechnology sold 2,301,581 shares of the stock in a transaction that occurred on Wednesday, April 4th. The shares were sold at an average price of $2.90, for a total value of $6,674,584.90. The disclosure for this sale can be found here. 7.90% of the stock is owned by corporate insiders.
Shares of ArQule stock traded down $0.17 during trading hours on Wednesday, hitting $2.70. The company’s stock had a trading volume of 939,778 shares, compared to its average volume of 737,753. ArQule has a 12 month low of $0.92 and a 12 month high of $3.35. The company has a market capitalization of $250.01, a P/E ratio of -6.92 and a beta of 0.81. The company has a debt-to-equity ratio of 1.03, a current ratio of 4.98 and a quick ratio of 4.98.
ArQule (NASDAQ:ARQL) last announced its quarterly earnings results on Monday, March 5th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.09). During the same period in the prior year, the company earned ($0.10) earnings per share. equities analysts anticipate that ArQule will post -0.24 EPS for the current fiscal year.
ArQule, Inc, a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. Its lead product candidate is tivantinib (ARQ 197), a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer.
Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with MarketBeat.com's FREE daily email newsletter.